Horphag Research Ltd. v. Consac Industries, Inc.

116 F.3d 1450, 1997 WL 374950
CourtCourt of Appeals for the Federal Circuit
DecidedApril 22, 1997
DocketNo. 96-1520
StatusPublished
Cited by1 cases

This text of 116 F.3d 1450 (Horphag Research Ltd. v. Consac Industries, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Horphag Research Ltd. v. Consac Industries, Inc., 116 F.3d 1450, 1997 WL 374950 (Fed. Cir. 1997).

Opinion

PLAGER, Circuit Judge.

International Nutrition Company (“INC”) and Egbert Schwitters (collectively referred to as “appellants”) appeal from an Order of the United States District Court for the Eastern District of New York in Doc. No. 93-CV-2522 dated May 8, 1996. That Order joined INC and Schwitters as parties under Federal Rules of Civil Procedure 25(c) and 71 to a case closed some ten months prior and bound them to the outcome therein. Because we conclude that neither Rule 25(c) nor Rule 71 applies to the present case and that the judge failed to make the proper findings of fact to support the concomitant injunction, we vacate the Order and remand with in[1452]*1452structions to deny the motion to join INC and Schwitters as parties.

BACKGROUND

The procedural history of the present case is complicated. We recite here only those facts necessary to elucidate our opinion. On June 8,1993, Horphag Research Ltd. (“Hor-phag”) and M.W. International, Inc. (“MW”) sued Consac Industries, Inc. (“Consac”) in the Eastern District of New York for (1) infringement of their registered United States trademark PYCNOGENOL, and (2) infringement of United States Patent No. 4,698,360 (the ’360 patent). At the time of this suit, Horphag owned an undivided 50% interest in the ’360 patent. The other 50% was owned by Societe Civile D’lnvestigations Phramacologiques D’Aquitaine (“SCIPA”). Neither Horphag nor Consac moved to join SCIPA as a party.

On October 15, 1993, Consac brought a declaratory judgment action in the United States District Court for the District of Columbia for invalidity of the ’360 patent against SCIPA and Societe Civile Pour L’Expansion de la Rechereche en Phytochimie Appliquee (“SCERPA”) pursuant to 35 U.S.C. § 293. At that time, SCERPA owned the rights to the registered French trademark PYCNOGENOLS but had no interest in the ’360 patent.

On March 7, 1994, SCERPA transferred its trademark rights in the French trademark to INC. On the same day, SCIPA transferred its 50% interest in the ’360 patent to INC. This transfer occurred approximately ten days after Consac filed a motion to transfer and consolidate its declaratory judgment action with the pending infringement action in the Eastern District of New York. Consac’s motion to consolidate the actions was granted on March 25, 1994, approximately two weeks after the transfers of rights occurred.

On April 8, 1994, SCIPA and SCERPA, now joined in the action against Horphag, answered Consac’s declaratory judgment complaint by asserting that the court lacked personal and subject matter jurisdiction because, inter alia, SCIPA had assigned its rights in the ’360 patent to INC. SCIPA and SCERPA also asserted three cross-claims against Horphag and MW. The only one relevant to the present appeal is the second that claimed that “Horphag and its agents fraudulently misappropriated SCERPA’s trademark for Horphag’s exclusive use and benefit in the United States in violation of Horphag’s agreement with SCERPA to respect SCERPA’s prior rights thereto.”

On November 16, 1994, the District Court entered an Order dismissing SCIPA and SCERPA’s cross-claims against Horphag and MW with prejudice, but provided that such dismissal “is without prejudice to the assertion thereof as counter-claims or cross-claims should Horphag or MW sue SCIPA or SCERPA in the United States, or elsewhere.” Subsequently, on July 26, 1995, Horphag and MW settled their trademark and patent infringement action against Con-sac. Pursuant to the settlement agreement all claims and counterclaims were dismissed with prejudice.

On September 9, 1995, INC filed with the United States Patent and Trademark Office (“PTO”) a Petition for Cancellation of Hor-phag’s United States registration of the trademark PYCNOGENOL. In that petition, INC alleged that Horphag had fraudulently obtained the registration in contravention of United States’ law and the Paris Convention. In 1992, SCIPA, INC’s predecessor in interest to the French trademark, had entered an opposition to Horphag’s application to register the trademark, but that opposition subsequently was dismissed with prejudice for failure to prosecute the opposition.

On March 14, 1996, Horphag and MW moved in the District Court of the Eastern District of New York to join INC and Schwitters as parties under Rules 25(c) and 71 to the then closed case formerly in that court. The court granted the motion, stating that INC and Schwitters were the “successor in interest” to SCERPA and SCIPA. As such, the Order explicitly bound INC and Schwitters to the court’s prior Order dismissing SCERPA and SCIPA’s cross-claims. In addition, INC was ordered to withdraw its [1453]*1453pending opposition proceeding in the PTO. INC now appeals that Order.

DISCUSSION

There are several problems with the court’s Order. First, Rule 25 does not apply to the present situation. Rule 25(c) provides that:

In case of any transfer of interest, the action may be continued by or against the original party, unless the court upon motion directs the person to whom the interest is transferred to be substituted in the action or joined with the original party.

Fed.R.Civ.P. 25(c). This rule only applies to pending litigation. See 3B Jeremy C. Moore et al., Moore’s Federal Practice ¶ 25.08 (2d ed. 1996) (“Subdivision (c) of Rtile 25 deals with transfers of interest during the course of the action.”); Panther Pumps & Equip. Co. v. Hydrocraft, Inc., 566 F.2d 8, 11 (7th Cir.1977); Minnesota Mining & Mfg. Co. v. Eco Chem, Inc., 757 F.2d 1256, 1262 (Fed.Cir.1985) (joinder under Rule 25(e) proper when transfer occurred during pendency of suit).

It is clear that at the time of the transfers by SCIPA and SCERPA to INC, neither were parties in the patent infringement suit brought by Horphag against Consac. Although Consac’s still separate declaratory judgment suit against SCIPA and SCERPA was pending in the District of Columbia court at the time of the transfers, that is irrelevant. The suit that must be pending is the one in which joinder is sought. Horphag attempts to rely on the filing date of Consac’s case against SCERPA and SCIPA because a motion to transfer and consolidate that suit with its suit against Consac was pending at the time of the transfer. Horphag has cited no authority for this proposition and we reject it. Horphag argues that a parade of horribles will occur if we permit INC to escape the court’s jurisdiction by transferring its interest. We doubt Hoiphag’s predictions will come true. We suspect that most suits will be originally brought against the correct party and that any subsequent transfer to avoid the court’s reach will trigger Rule 25(c). Accordingly, we hold that INC and Schwitters were improperly joined under Rule 25(c).

Rule 71 is equally unavailing.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
116 F.3d 1450, 1997 WL 374950, Counsel Stack Legal Research, https://law.counselstack.com/opinion/horphag-research-ltd-v-consac-industries-inc-cafc-1997.